{"prompt": "['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', 'If it is clinically needed, then blinding may be broken either for a selected AE or', 'for the full interim data.', 'Substantial safety concerns:', 'The interim safety dataset will be analyzed by vaccination group and blinding will', 'be discontinued for these data.', 'The safety panel will consist of three to four expert physicians who are not investigators on this', 'study. The physicians will consist of staff from the CDC and from CISA site(s) other than Duke', 'or BMC, including at least one internal medicine physician. The panel will meet initially before', 'study enrollment to review the study and the monitoring plan and to share background', 'information about what is known about allV and IIV3-HD safety (package insert review). A', 'meeting will be scheduled in 2018 for an interim review of safety data. Study investigators and', 'statisticians will be invited to participate, and the meetings will consist of open discussions', 'between the panel and study investigators (under CISA confidentially agreement). Ad hoc', 'meetings will be scheduled as needed.', '79']['Version 5.0', 'FLUAD vs Fluzone-HD', 'September 25, 2018', 'Appendix I: LLFDI-CAT', '80']['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', 'Appendix J: EQ-5D-5L and VAS', '118']\n\n###\n\n", "completion": "END"}